药物基本信息
通用名：曲妥珠单抗
适应症：适用于HER2 过度表达的转移性乳腺癌：作为单一药物治疗已接受过1 个或多个化疗方案的转移性乳腺癌;与紫杉醇或者多西他赛联合，用于未接受化疗的转移性乳腺癌患者。
市场需求
曲妥珠单抗，是抗Her 2的单克隆抗体，它通过将自己附着在Her2上来阻止人体表皮生长因子在Her2上的附着，从而阻断癌细胞的生长，赫赛汀还可以刺激身体自身的免疫细胞去摧毁癌细胞。临床上目前主要用于Her-2过度表达的转移性乳腺癌。单药治疗可用于已接受过一个或多个化疗方案的转移性乳腺癌；可与紫杉醇联合治疗未接受过化疗的转移性乳腺癌。
曲妥珠单抗是罗氏开发的重磅产品，2016年全国销售额达30亿元，年增长率12.21%。该品种在国内属于仅次于利妥昔单抗的第二大单抗药物。
The basic information of drug
Common name: Trastuzumab
Indications: treatment of HER2 overexpressed metastatic breast cancer: it is treated as a single drug for metastatic breast cancer that has received one or more chemotherapy regimens; combined with paclitaxel or docetaxel for metastatic breast cancer patients who have not received chemotherapy.
Market demand
Trastuzumab is a monoclonal antibody against Her 2 which inhibits the body's own immune cells to destroy cancer through attaching itself to Her2 to prevent the attachment of human epidermal growth factor to Her2, thereby blocking the growth of cancer cells. Herceptin can also stimulate the body's own immune cells to destroy cancer cells. At present, it is mainly used for Her-2 overexpression of metastatic breast cancer clinically. Monotherapy can be used for metastatic breast cancer that has received one or more chemotherapy regimens; it can be combined with paclitaxel for metastatic breast cancer without chemotherapy.
Trastuzumab is heavy products developed by Roche. In 2016, the national sales of it are 30 billion yuan and annual growth rate is 12.21%. The species is second largest monoclonal antibody second only to rituximab in the country.
(曲妥珠单抗治疗HER2阳性转移性乳腺癌,图片来源诺禾致源)
